1. Introduction {#sec1-pharmacy-08-00025}
===============

Opioid use rates have doubled (from 4.1% to 9.0%) among older adults (65 years and older) in the United States (US) in recent years \[[@B1-pharmacy-08-00025]\]. As a result, there are more opioid-related problems (e.g., addiction, adverse drug events), with deaths increasing by 345% between 2001 and 2016 \[[@B2-pharmacy-08-00025]\]. While the recent opioid crisis has heightened awareness among the medical community, policy makers, and the general public \[[@B3-pharmacy-08-00025],[@B4-pharmacy-08-00025]\], co-prescribing of opioids and benzodiazepines remains widespread. This is particularly concerning given the potential for associated adverse drug events, morbidity, and mortality \[[@B5-pharmacy-08-00025]\]. Recently, the Centers for Disease Control and Prevention released guidelines specifically aimed at reducing overprescribing of opioids and avoiding concurrent use of opioids and benzodiazepines (potentiator drugs) \[[@B6-pharmacy-08-00025]\]; potentiator drugs enhance the effects of an opioid medication when taken concurrently and may cause serious problems \[[@B7-pharmacy-08-00025],[@B8-pharmacy-08-00025]\]. The magnitude of co-prescribing of these two drugs is an ongoing problem, and thus, it must remain a top priority in the healthcare arena.

Primary care providers (PCPs) typically are the first to intervene with patients, prescribing approximately 50% of all opioids \[[@B9-pharmacy-08-00025]\]. However, many PCPs find it difficult to manage these patients given the complexity of their cases and limited knowledge regarding available resources (e.g., prescribing guidelines, pain scales) \[[@B9-pharmacy-08-00025]\].

To this end, pharmacists are in a unique position, given their extensive clinical training in medication management and identifying medication-related problems (e.g., drug--drug interactions, dosing concerns, drug--disease interactions, adverse drug events (ADEs), monitoring concerns, and therapeutic duplication avoidance) to help address inappropriate use of opioids \[[@B10-pharmacy-08-00025],[@B11-pharmacy-08-00025]\], and concurrent use of opioids and benzodiazepines via medication therapy management (MTM) \[[@B12-pharmacy-08-00025]\]. Additionally, pharmacists play an integral role in mitigating these avoidable opioid-related drug interactions. \[[@B13-pharmacy-08-00025]\] Pharmacist-delivered MTM services comprise a compendium of services designed to optimize health outcomes and reduce ADEs, including those associated with concurrent use of opioids and benzodiazepines \[[@B11-pharmacy-08-00025],[@B14-pharmacy-08-00025]\].

Previous studies have investigated the outcomes associated with pharmacist-delivered, direct-to-provider interventions in reducing use of potentially inappropriate medications (PIMs) \[[@B10-pharmacy-08-00025],[@B15-pharmacy-08-00025]\]. Monane et al. found that a pharmacist-delivered, telephonic (telehealth) prescriber intervention was successful in reducing the prescribing of PIMs in the elderly (e.g., Beers List) \[[@B14-pharmacy-08-00025]\]. Another direct-to-provider intervention study decreased opioid utilization for chronic pain, improved adherence to guidelines, and showed a significant decrease in co-prescribing of opioids with benzodiazepines \[[@B10-pharmacy-08-00025]\].

Yet, little is still known about the impact of pharmacist-delivered MTM interventions, specifically addressing co-prescribing of opioids and benzodiazepines. To address this gap, the study objectives were to describe the: (1) number of pharmacist-delivered MTM interventions to reduce co-prescribing of opioids and benzodiazepines; (2) most commonly co-prescribed opioids and benzodiazepines; and (3) number of and differences in primary care provider-accepted recommendations based on patient age, gender, and prescriber region over a one-year period.

2. Materials and Methods {#sec2-pharmacy-08-00025}
========================

2.1. Study Design and Data Source {#sec2dot1-pharmacy-08-00025}
---------------------------------

This descriptive study involved a retrospective review of prescription claims data, provided by a national MTM sponsor during the period between 1 January to 31 December 2016. This project was approved by the University of Arizona Institutional Review Board.

2.2. Study Participants {#sec2dot2-pharmacy-08-00025}
-----------------------

Subjects identified in the dataset were included if they: received a telephonic, targeted medication review (TMR), were 18 years of age or older, and taking one opioid and one benzodiazepine concurrently.

2.3. Pharmacist-Delivered, Direct-to-Provider Interventions {#sec2dot3-pharmacy-08-00025}
-----------------------------------------------------------

A national MTM sponsor, housed at a dedicated, academic site, conducted automated TMRs to identify patients with concurrent prescriptions for opioids and benzodiazepines; as part of the TMR, the telepharmacist recommended discontinuing one of the co-prescribed drugs, using a standardized, call script designed to help maintain consistency in patient messaging. This automated TMR process used computerized algorithms to determine simultaneous fill dates and day supplies of medications in the two drug classes. The algorithm triggered "autoalerts" that were reviewed by pharmacy staff and authorized by a clinical telehealth pharmacist. If a provider intervention was deemed appropriate, a recommendation was delivered to the patient's prescriber(s) via facsimile. These interventions focused on recommendations evaluating the patient's safety risks associated with co-prescribed opioids and benzodiazepines. Pharmacy claims data were reviewed for 120 days following the intervention and deemed successful if the medication combination was not dispensed during that timeframe (e.g., discontinuation of at least one of these drug).

2.4. Data Collection and Analysis {#sec2dot4-pharmacy-08-00025}
---------------------------------

Deidentified data were extracted from the prescription claims database for the 2016 calendar year. Variables of interest included: patient age and gender; provider geographic location; name and quantity of opioid medications prescribed; name and quantity of benzodiazepine medications prescribed; number and type of pharmacist-to-provider recommendations made to reduce co-prescribing of opioids and benzodiazepines; name and number of opioid and benzodiazepine medication(s) discontinued. Descriptive statistics and chi-square tests were computed using SAS v9.4 (Cary, NC, USA). An alpha value of 0.05 was selected a priori. Post-hoc chi-square tests were conducted to assess differences between regions, and a Bonferroni correction (*p* = 0.05/6 = 0.0083) was applied.

3. Results {#sec3-pharmacy-08-00025}
==========

3.1. Sample Characteristics {#sec3dot1-pharmacy-08-00025}
---------------------------

The study sample consisted of 57,748 subjects who were concurrently co-prescribed an opioid and benzodiazepine. Approximately two-thirds of the study sample were female (67.83%) and aged 65 years or older (66.90%). Prescribers were most commonly located in the southern region (46.88%), followed by midwestern (28.93%), northeastern (17.06%) and western (7.13%) regions of the US (See [Table 1](#pharmacy-08-00025-t001){ref-type="table"}).

3.2. Most Commonly Co-Prescribed Medications {#sec3dot2-pharmacy-08-00025}
--------------------------------------------

The top five opioid medications co-prescribed with benzodiazepines were hydrocodone-acetaminophen (*n* = 19,401, 33.60%), tramadol HCL (*n* = 10,107, 17.50%), oxycodone-acetaminophen (*n* = 9045, 15.66%), oxycodone HCL (*n* = 5349, 9.26%), and acetaminophen-codeine (*n* = 2640, 4.57%). [Table A1](#pharmacy-08-00025-t0A1){ref-type="table"} provides the full list of concurrently prescribed opioid medication with benzodiazepine medications.

The top five benzodiazepine medications co-prescribed with opioids were alprazolam (*n* = 20,275, 35.11%), clonazepam (*n* = 12,222, 21.16%), lorazepam (*n* = 11,599, 20.09%), diazepam (*n* = 6988, 12.10%), and temazepam (*n* = 4233, 7.33%). [Table A2](#pharmacy-08-00025-t0A2){ref-type="table"} provides the full list of concurrently prescribed benzodiazepine medications with opioid medications.

3.3. Recommendations Made and Accepted {#sec3dot3-pharmacy-08-00025}
--------------------------------------

For each subject, the clinical pharmacist made a direct-to-provider recommendation via facsimile to discontinue one of the medications. A total of 37,990 medications were discontinued, including opioids (*n* = 22,708, 59.77%) and benzodiazepines (*n* = 15,282, 40.23%), resulting in a 65.79% prescriber acceptance rate of pharmacists' recommendations. Subjects whose prescribers accepted the pharmacist's deprescribing recommendation were similar to the overall sample for females (*n* = 26,067 of 37,990, 68.6% versus *n* = 31,970 of 57,748, 67.83%) and those 65 or older (*n* = 27,063 of 37,990, 71.2% versus *n* = 38,633 of 57,748, 66.90%). Significant differences were observed in the proportion of opioids discontinued based on subject age (*p* \< 0.001) and geographical region of prescriber (*p* = 0.0148) (see [Table 2](#pharmacy-08-00025-t002){ref-type="table"}).

The top five medications discontinued by the prescriber in response to recommendations made by the clinical pharmacist to reduce co-prescribing of opioid and benzodiazepines were hydrocodone-acetaminophen (*n* = 7165, 18.86%), alprazolam (*n* = 5390, 14.19%), tramadol HCl (*n* = 5131, 13.51%), lorazepam (*n* = 3547 9.34%), and oxycodone-acetaminophen (*n* = 3365 8.86%). [Table A3](#pharmacy-08-00025-t0A3){ref-type="table"} lists the medications discontinued by prescribers to reduce co-prescribing of these two drugs.

4. Discussion {#sec4-pharmacy-08-00025}
=============

This descriptive study highlights commonly co-prescribed opioid and benzodiazepine medications, identified in a prescription claims database. It also provides preliminary evidence to suggest that pharmacist direct-to-provider interventions, following an MTM consultation, may help in reducing co-prescribing of opioids and benzodiazepines.

Provider acceptance (65.79%) of pharmacist interventions, was higher than some rates previously reported \[[@B15-pharmacy-08-00025],[@B16-pharmacy-08-00025],[@B17-pharmacy-08-00025]\]. Interestingly, Perera et al. found that pharmacist-delivered provider interventions communicated via facsimile had reported lower provider acceptance rates, particularly those related to guideline adherence and safety concerns \[[@B17-pharmacy-08-00025]\]. An evaluation of recommendations made by MTM pharmacists, as part of an interprofessional chronic care management program, found that 37.5% (*N* = 200) of recommendations were accepted by providers \[[@B15-pharmacy-08-00025]\]. Others have reported acceptance rates ranging from 42% to 60% in a community pharmacy setting and an average of 47% in a telehealth setting \[[@B16-pharmacy-08-00025],[@B17-pharmacy-08-00025]\]. While the current study acceptance rate is higher compared to other interventions and practice settings, opportunities for improvement remain. The reasons for the somewhat higher provider acceptance rate in the current study are unknown. However, several potential explanations include subject characteristics, greater recognition of the value of pharmacist-provided MTM services, and/or the current public health priority focused on addressing the opioid epidemic.

The current study found that some providers deprescribed (either an opioid or benzodiazepine), yet the reasons for doing so are not well understood. Another study found that a direct-to-provider intervention reduced opioid dosing and significantly decreased co-prescribing of opioids with benzodiazepines \[[@B10-pharmacy-08-00025]\]. However, identifying effective strategies to urge prescribers to dose reduce and/or deprescribe opioids and benzodiazepines is not without its challenges. Barriers still remain such as employing effective communication channels to ensure receipt of the pharmacist's recommendations, prescriber knowledge regarding patients' risk for adverse drug events, and lack of resources and institutional support for deprescribing and providing viable alternatives \[[@B18-pharmacy-08-00025]\].

However, some patients still may resist deprescribing if they feel the health condition that they were using drugs to manage is critical to effective symptom management and their current treatment. In a recent study, patients expressed healthcare system factors and positive personal experiences with sedative medication usage as reasons for disputing providers' recommendation to deprescribe while being concerned about safe alternatives \[[@B18-pharmacy-08-00025]\]. Yet, numerous, viable alternatives exist rather than relying on co-prescribing opioids and benzodiazepines. For example, previous studies have found that individuals with chronic pain effectively use a variety of strategies to manage it, including both pharmacological and non-pharmacological approaches \[[@B19-pharmacy-08-00025]\]. Furthermore, another study found that pharmacists with chronic pain used a mean of 13 ± 5 pharmacological and non-pharmacological management strategies, while some used as many as 31 different ones \[[@B20-pharmacy-08-00025]\]. Additionally, direct-to-patient educational interventions may provide promising opportunities, especially when coupled with individualized care \[[@B18-pharmacy-08-00025]\].

There were limitations with this study. First, it used a prescription claims database, and thus it was impossible to determine whether the medication was actually taken, if prescriptions were purchased with cash or obtained from a prescriber beyond their primary provider, or if the patient was non-compliant with prescription discontinuation and continued to take medications on-hand thereafter. Second, while the sample size was large, limited details such as a verbal or written response from the provider to the pharmacist recommendation, were available beyond whether an intervention was made and accepted. Third, this study used a sample of Medicare beneficiaries, and thus the generalizability is limited to this population. Fourth, the study had a relatively short follow-up period of 120 days, limiting its generalizability. Lastly, lack of information on the number of alerts compared to total recommendations may have contributed bias in the study regarding provider acceptance rates. Further investigation is warranted to study whether pharmacist interventions are effective in reducing co-prescription of opioids and other potentiator medications as well as exploring if deprescribing rates are maintainable over a longer study period (\>4 months).

5. Conclusions {#sec5-pharmacy-08-00025}
==============

This study involving prescription claims data described the characteristics of patients and the most commonly co-prescribed opioids and benzodiazepines discontinued following a pharmacist-delivered, direct-to-provider intervention. These study findings suggest that pharmacist-initiated, direct-to-prescriber communication may help reduce co-prescribing of opioids and benzodiazepines in a Medicare population. However, more work is needed, using a more comprehensive data source and analytical study design, to investigate types of pharmacist interventions made and intervention types accepted by providers. Further research is warranted to evaluate whether these same results are achievable with opioids and other potentiator medications, and to investigate this pharmacist-delivered medication therapy management program in more diverse populations and settings.
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pharmacy-08-00025-t0A1_Table A1

###### 

List of opioid medications co-prescribed with benzodiazepine medications (*N* = 57,748).

  Opioid Name                       *N*          \%
  --------------------------------- ------------ -----------
  ABSTRAL                           1            0.00
  ACETAMIN-CAFF-DIHYDROCODEINE      1            0.00
  **ACETAMINOPHEN-CODEINE**         **2640**     **4.57**
  ARYMO ER                          2            0.00
  ASCOMP WITH CODEINE               12           0.02
  BELBUCA                           33           0.06
  BUPRENORPHINE                     70           0.12
  BUTALB-ACETAMINOPH-CAFF-CODEINE   35           0.06
  BUTALB-CAFF-ACETAMINOPH-CODEINE   36           0.06
  BUTALBITAL COMPOUND-CODEINE       34           0.06
  BUTORPHANOL TARTRATE              38           0.07
  BUTRANS                           307          0.53
  CARISOPRODOL-ASPIRIN-CODEINE      1            0.00
  CODEINE SULFATE                   27           0.05
  CONZIP                            2            0.00
  DEMEROL                           5            0.01
  DILAUDID                          22           0.04
  DURAGESIC                         30           0.05
  EMBEDA                            41           0.07
  ENDOCET                           290          0.50
  EXALGO                            8            0.01
  FENTANYL                          1945         3.37
  FENTANYL CITRATE                  7            0.01
  FIORICET WITH CODEINE             2            0.00
  FIORINAL WITH CODEINE \#3         10           0.02
  HYDROCODONEBT-HOMATROPINE MBR     1            0.00
  **HYDROCODONE-ACETAMINOPHEN**     **19,401**   **33.60**
  HYDROCODONE-CHLORPHENIRAMNE ER    143          0.25
  HYDROCODONE-HOMATROPINE MBR       91           0.16
  HYDROCODONE-IBUPROFEN             60           0.10
  HYDROMET                          49           0.08
  HYDROMORPHONE ER                  62           0.11
  HYDROMORPHONE HCL                 837          1.45
  HYSINGLA ER                       63           0.11
  IBUDONE                           1            0.00
  KADIAN                            6            0.01
  LEVORPHANOL TARTRATE              8            0.01
  LORCET                            6            0.01
  LORCET HD                         9            0.02
  LORCET PLUS                       3            0.01
  LORTAB                            11           0.02
  MEPERIDINE HCL                    23           0.04
  METHADONE HCL                     501          0.87
  METHADONE INTENSOL                1            0.00
  METHADOSE                         1            0.00
  MORPHABOND ER                     1            0.00
  MORPHINE SULFATE                  553          0.96
  MORPHINE SULFATE ER               2014         3.49
  MS CONTIN                         3            0.01
  NORCO                             78           0.14
  NUCYNTA                           135          0.23
  NUCYNTA ER                        105          0.18
  OPANA                             6            0.01
  OPANA ER                          91           0.16
  OXAYDO                            4            0.01
  **OXYCODONE HCL**                 **5349**     **9.26**
  OXYCODONE HCL ER                  336          0.58
  OXYCODONE HCL-ASPIRIN             11           0.02
  OXYCODONE HCL-IBUPROFEN           1            0.00
  **OXYCODONE-ACETAMINOPHEN**       **9045**     **15.66**
  OXYCONTIN                         1203         2.08
  OXYMORPHONE HCL                   82           0.14
  OXYMORPHONE HCL ER                299          0.52
  PERCOCET                          113          0.20
  PROMETHAZINE-CODEINE              408          0.71
  ROXICODONE                        9            0.02
  SUBSYS                            7            0.01
  **TRAMADOL HCL**                  **10,107**   **17.50**
  TRAMADOL HCL ER                   207          0.36
  TRAMADOL HCL-ACETAMINOPHEN        424          0.73
  TREZIX                            1            0.00
  TUSSIGON                          1            0.00
  TUSSIONEX                         11           0.02
  TUZISTRA XR                       1            0.00
  TYLENOL-CODEINE NO.3              32           0.06
  TYLENOL-CODEINE NO.4              3            0.01
  ULTRACET                          12           0.02
  ULTRAM                            22           0.04
  VICODIN                           61           0.11
  VICODIN ES                        31           0.05
  VICODIN HP                        12           0.02
  VITUZ                             2            0.00
  XARTEMIS XR                       2            0.00
  XODOL 7.5--300                    1            0.00
  XTAMPZA ER                        48           0.08
  ZOHYDRO ER                        41           0.07

Note: Bold font indicates the top five opioid medications.

pharmacy-08-00025-t0A2_Table A2

###### 

List of benzodiazepine medications co-prescribed with opioid medications (*N* = 57,748).

  Benzodiazepine Name              *N*          \%
  -------------------------------- ------------ -----------
  **ALPRAZOLAM**                   **20,275**   **35.11**
  ALPRAZOLAM ER                    132          0.23
  ALPRAZOLAM ODT                   35           0.06
  ALPRAZOLAM XR                    75           0.13
  ATIVAN                           118          0.20
  CHLORDIAZEPOXIDE HCL             154          0.27
  CHLORDIAZEPOXIDE-AMITRIPTYLINE   40           0.07
  CHLORDIAZEPOXIDE-CLIDINIUM       121          0.21
  **CLONAZEPAM**                   **12,222**   **21.16**
  CLORAZEPATE DIPOTASSIUM          475          0.82
  **DIAZEPAM**                     **6988**     **12.10**
  ESTAZOLAM                        43           0.07
  FLURAZEPAM HCL                   77           0.13
  HALCION                          11           0.02
  KLONOPIN                         58           0.10
  LIBRAX                           54           0.09
  **LORAZEPAM**                    **11,599**   **20.09**
  LORAZEPAM INTENSOL               14           0.02
  NIRAVAM                          1            0.00
  ONFI                             14           0.02
  OXAZEPAM                         150          0.26
  RESTORIL                         38           0.07
  **TEMAZEPAM**                    **4233**     **7.33**
  TRANXENE T-TAB                   3            0.01
  TRIAZOLAM                        300          0.52
  VALIUM                           139          0.24
  XANAX                            372          0.64
  XANAX XR                         7            0.01

Bold font indicates the top five benzodiazepine medications.

pharmacy-08-00025-t0A3_Table A3

###### 

Medications discontinued by prescriber following pharmacist recommendations aimed to reduce co-prescribing of opioid and benzodiazepine medications (*N* = 37,990).

  Pharmacist Recommendation to Prescriber to Remove:   *N*        \%
  ---------------------------------------------------- ---------- -----------
  ACETAMIN-CAFF-DIHYDROCODEINE                         1          0.00
  ACETAMINOPHEN-CODEINE                                1698       4.47
  **ALPRAZOLAM**                                       **5390**   **14.19**
  ALPRAZOLAM ER                                        40         0.11
  ALPRAZOLAM ODT                                       20         0.05
  ALPRAZOLAM XR                                        37         0.10
  ASCOMP WITH CODEINE                                  6          0.02
  ATIVAN                                               6          0.02
  BELBUCA                                              9          0.02
  BUPRENORPHINE                                        37         0.10
  BUTALB-ACETAMINOPH-CAFF-CODEINE                      13         0.03
  BUTALB-CAFF-ACETAMINOPH-CODEINE                      15         0.04
  BUTALBITAL COMPOUND-CODEINE                          12         0.03
  BUTORPHANOL TARTRATE                                 14         0.04
  BUTRANS                                              151        0.40
  CARISOPRODOL-ASPIRIN-CODEINE                         1          0.00
  CHLORDIAZEPOXIDE HCL                                 61         0.16
  CHLORDIAZEPOXIDE-AMITRIPTYLINE                       5          0.01
  CHLORDIAZEPOXIDE-CLIDINIUM                           67         0.18
  CLONAZEPAM                                           2412       6.35
  CLORAZEPATE DIPOTASSIUM                              147        0.39
  CODEINE SULFATE                                      13         0.03
  DIAZEPAM                                             2227       5.86
  DILAUDID                                             2          0.01
  DURAGESIC                                            3          0.01
  EMBEDA                                               13         0.03
  ENDOCET                                              94         0.25
  ESTAZOLAM                                            6          0.02
  EXALGO                                               2          0.01
  FENTANYL                                             420        1.11
  FENTANYL CITRATE                                     1          0.00
  FIORINAL WITH CODEINE \#3                            1          0.00
  FLURAZEPAM HCL                                       28         0.07
  HALCION                                              1          0.00
  **HYDROCODONE-ACETAMINOPHEN**                        **7165**   **18.86**
  HYDROCODONE-CHLORPHENIRAMNE ER                       113        0.30
  HYDROCODONE-HOMATROPINE MBR                          70         0.18
  HYDROCODONE-IBUPROFEN                                32         0.08
  HYDROMET                                             40         0.11
  HYDROMORPHONE ER                                     17         0.04
  HYDROMORPHONE HCL                                    359        0.94
  HYSINGLA ER                                          22         0.06
  IBUDONE                                              1          0.00
  KADIAN                                               6          0.02
  KLONOPIN                                             8          0.02
  LEVORPHANOL TARTRATE                                 3          0.01
  LIBRAX                                               20         0.05
  **LORAZEPAM**                                        **3547**   **9.34**
  LORAZEPAM INTENSOL                                   12         0.03
  LORCET                                               3          0.01
  LORCET HD                                            7          0.02
  LORCET PLUS                                          2          0.01
  LORTAB                                               2          0.01
  MEPERIDINE HCL                                       10         0.03
  METHADONE HCL                                        97         0.26
  METHADONE INTENSOL                                   1          0.00
  MORPHINE SULFATE                                     235        0.62
  MORPHINE SULFATE ER                                  446        1.17
  MS CONTIN                                            1          0.00
  NORCO                                                10         0.03
  NUCYNTA                                              60         0.16
  NUCYNTA ER                                           43         0.11
  OPANA                                                5          0.01
  OPANA ER                                             60         0.16
  OXAYDO                                               1          0.00
  OXAZEPAM                                             27         0.07
  OXYCODONE HCL                                        1604       4.22
  OXYCODONE HCL ER                                     162        0.43
  OXYCODONE HCL-ASPIRIN                                4          0.01
  OXYCODONE HCL-IBUPROFEN                              1          0.00
  **OXYCODONE-ACETAMINOPHEN**                          **3365**   **8.86**
  OXYCONTIN                                            261        0.69
  OXYMORPHONE HCL                                      23         0.06
  OXYMORPHONE HCL ER                                   82         0.22
  PERCOCET                                             18         0.05
  PROMETHAZINE-CODEINE                                 323        0.85
  RESTORIL                                             3          0.01
  SUBSYS                                               1          0.00
  TEMAZEPAM                                            1095       2.88
  **TRAMADOL HCL**                                     **5131**   **13.51**
  TRAMADOL HCL ER                                      65         0.17
  TRAMADOL HCL-ACETAMINOPHEN                           235        0.62
  TREZIX                                               1          0.00
  TRIAZOLAM                                            63         0.17
  TUSSIONEX                                            2          0.01
  TUZISTRA XR                                          1          0.00
  TYLENOL-CODEINE NO.3                                 3          0.01
  ULTRACET                                             4          0.01
  ULTRAM                                               6          0.02
  VALIUM                                               22         0.06
  VICODIN                                              43         0.11
  VICODIN ES                                           16         0.04
  VICODIN HP                                           8          0.02
  XANAX                                                34         0.09
  XANAX XR                                             4          0.01
  XARTEMIS XR                                          2          0.01
  XODOL 7.5-300                                        1          0.00
  XTAMPZA ER                                           21         0.06
  ZOHYDRO ER                                           8          0.02

Note: Bold font indicates the top five medications removed by the prescriber in response to recommendations made by the pharmacist to reduce co-prescribing of opioid and benzodiazepine medications.

pharmacy-08-00025-t001_Table 1

###### 

Demographic characteristics of study subjects co-prescribed an opioid and a benzodiazepine medication (*N* = 57,748).

  Characteristic                          *N*           \%       
  --------------------------------------- ------------- -------- -------
  **Gender**                                                     
                                          Female        39,170   67.83
                                          Male          18,578   32.17
  **Age, Years**                                                 
                                          \<65          19,115   33.10
                                          65 or older   38,633   66.90
  **Geographical Region of Prescriber**                          
                                          Northeast     9853     17.06
                                          Midwest       16,705   28.93
                                          South         27,073   46.88
                                          West          4115     7.13

pharmacy-08-00025-t002_Table 2

###### 

Demographic characteristics of study subjects whose prescriber accepted the pharmacist recommendation to discontinue an opioid or benzodiazepine (*n* = 37,990).

  Characteristic                      Total *N*     Opioid *n* (%)   Benzodiazepine *n* (%)   *p* Value        
  ----------------------------------- ------------- ---------------- ------------------------ ---------------- --
  **Total**                                         22,708 (59.77)   15,282 (40.23)                            
  Gender                                                                                      0.2250           
                                      Female        26,067           15,635 (59.98)           10,432 (40.02)   
                                      Male          11,923           7073 (59.32)             4850 (40.68)     
  Age, years                                                                                  \<0.0010         
                                      \<65          10,927           6146 (56.25)             4781 (43.75)     
                                      65 or older   27,063           16,562 (61.20)           10,501 (38.80)   
  Geographical region of prescriber                                                           0.0148           
                                      Northeast     6804             4171 (61.30)             2633 (38.70)     
                                      Midwest       10,965           6540 (59.64)             4425 (40.36)     
                                      South         17,270           10,282 (59.54)           6988 (40.46)     
                                      West          2948             1713 (58.11)             1235 (41.89)     

Note: Post-hoc analyses indicated a significant difference between Northeast and West regions (*p* = 0.0031). There was no difference between the other regions (*p* \> 0.0083).
